Topic
Argatroban
About: Argatroban is a research topic. Over the lifetime, 1433 publications have been published within this topic receiving 34474 citations. The topic is also known as: (21R)-argatroban anhydrous & argatroban.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This article suggests that platelet count monitoring should be performed every 2 or 3 days for patients receiving heparin in whom clinicians consider the risk of HIT to be > 1%, and suggests the use of argatroban or lepirudin or danaparoid over other nonheparin anticoagulants.
880 citations
••
TL;DR: Three additional parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in patients with HIT, and fondaparinux-associated HIT or osteoporosis is unlikely to occur.
848 citations
••
TL;DR: VenousThrombosis complicates heparin-induced thrombocytopenia more frequently than does arterial thromBosis, and the high risk of thROMbosis in patients initially recognized with isolated throma suggests that conventional management approaches require reappraisal.
834 citations
••
TL;DR: This chapter about the recognition, treatment, and prevention of heparin-induced thrombocytopenia (HIT) is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines.
825 citations
••
TL;DR: In this paper, the recognition, treatment, and prevention of heparin-induced thrombocytopenia (HIT) is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
745 citations